The validated t(14;22) translocation was predicted to juxtapose the μ and 3’ enhancers (chr14:106032614–106167601) with DERL3. Hence, we looked for evidence of overexpression of DERL3 and other cancer-associated genes within 1 Mb of the predicted breakpoint on chromosome 22 (IGLL5, BCR, and SMARCB1) by examining RNA-seq expression data from a partially overlapping set of 84 MM patients. This evidence concerns the gene SMARCB1 and Miyoshi myopathy.